Sample size calculation and statistical analysis
SECONDARY
The statistical hypothesis is set with reference to the PFS of previous clinical studies in advanced GC. The PFS rate at 4 months was reported as approximately 27% in the FTD/TPI arm of the TAGS trial [The analyses of the primary and secondary efficacy endpoints are planned to be performed in the full analysis set, and additional analysis is planned in the intention-to-treat population and in the per protocol if necessary. The safety analysis is planned to be conducted in the safety analysis population.Patient characteristics will be compared using Pearson’s 